Our new, updated feature will showcase both audio and video journalism from The New York Times and invite student dialogue and reflection. By The Learning Network Where and how do you get your ...
Barcelona's gamble on youth is paying off, but will it last? Having turned to their youngsters in a moment of need, Barca have been repaid in brilliant fashion ahead of the club's first Champions ...
Once inspired by sports icons and international celebrities, tattoo enthusiasts today are making a statement by inking their bodies with their beliefs and moments defining their lives ...
Two leading glucagon-like peptide-1 (GLP-1) receptor agonists for obesity and type 2 diabetes – Novo Nordisk A/S’s semaglutide (Wegovy/Ozempic) and Eli Lilly and Co.’s tirzepatide (Mounjaro/Zepbound) ...
<!doctype html><html lang=en><head><meta charset=utf-8><meta name=viewport content="width=device-width,initial-scale=1"><meta http-equiv=x-ua-compatible content="IE ...
The FDA on Friday signed off on Eli Lilly’s therapeutic antibody lebrikizumab for the treatment of moderate-to-severe atopic dermatitis. Lilly will market the therapy under the brand name Ebglyss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback